{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T21:10:08Z","timestamp":1685567408279},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.eimc.2010.02.001","type":"journal-article","created":{"date-parts":[[2010,4,15]],"date-time":"2010-04-15T09:11:14Z","timestamp":1271322674000},"page":"253.e1-253.e17","source":"Crossref","is-referenced-by-count":0,"title":["Caracter\u00edsticas de los f\u00e1rmacos antiv\u00edricos activos frente al virus de la hepatitis y el virus de la influenza: actualizaci\u00f3n 2009"],"prefix":"10.1016","volume":"28","author":[{"given":"Ester","family":"Lopez-Su\u00f1\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montse","family":"Tuset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montse","family":"Laguno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asunci\u00f3n","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 M.","family":"Mir\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2010.02.001_bib1","series-title":"Cat\u00e1logo de Medicamentos. Colecci\u00f3n Consejo Plus","year":"2009"},{"key":"10.1016\/j.eimc.2010.02.001_bib2","series-title":"Drug Information Handbook 2009\u20132010","author":"Lacy","year":"2009"},{"key":"10.1016\/j.eimc.2010.02.001_bib3","unstructured":"Hopkins J. ABX Guide; Montvale, NJ; 2009 [consultado 5\/7\/2009]. Disponible en: http:\/\/hopkins-abxguide.org\/"},{"key":"10.1016\/j.eimc.2010.02.001_bib4","unstructured":"Klasco RK. DRUGDEX\u00ae System Colorado, USA: Thomson Micromedex, Greenwood Village; 2009 [consultado 5\/7\/2009]. Disponible en: http:\/\/www.thomsonhc.com."},{"key":"10.1016\/j.eimc.2010.02.001_bib5","series-title":"Gu\u00eda de terap\u00e9utica antimicrobiana 2009","author":"Mensa","year":"2009"},{"key":"10.1016\/j.eimc.2010.02.001_bib6","unstructured":"Product information. European Medicines Agency EMEA, Londres: 2009. [consultado 5\/7\/2009]. Disponible en: http:\/\/www.emea.europa.eu\/htms\/human\/epar\/a.htm."},{"key":"10.1016\/j.eimc.2010.02.001_bib7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1157\/13076175","article-title":"Documento de consenso GESIDA\/GESITRA-SEIMC, SPNS y ONT sobre trasplante de \u00f3rgano s\u00f3lido en pacientes infectados por el VIH en Espa\u00f1a marzo 2005","volume":"23","author":"Mir\u00f3","year":"2005","journal-title":"Enfermedades Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2010.02.001_bib8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1157\/13125642","article-title":"Prevenci\u00f3n de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el VIH en el a\u00f1o 2008. Recomendaciones del Grupo de Estudio del Sida GESIDA\/Plan Nacional sobre el Sida","volume":"26","year":"2008","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2010.02.001_bib9","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1002\/lt.21614","article-title":"Liver transplantation for hepatitis B: What is the best hepatitis B immune globulin\/antiviral regimen?","volume":"14","author":"Angus","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1016\/j.eimc.2010.02.001_bib10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1157\/13051908","article-title":"Caracter\u00edsticas de los f\u00e1rmacos antivirales","volume":"21","author":"Tuset","year":"2003","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2010.02.001_bib11","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/hep.21627","article-title":"Management of hepatitis B: Summary of a clinical research workshop","volume":"45","author":"Hoofnagle","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2010.02.001_bib12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2010.02.001_bib13","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.4321\/S1137-66272004000400002","article-title":"Virolog\u00eda, epidemiolog\u00eda y mecanismos de transmisi\u00f3n del VHB","volume":"27","author":"Moreno","year":"2004","journal-title":"An Sist Sanit Navar"},{"key":"10.1016\/j.eimc.2010.02.001_bib14","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1053\/gast.2002.37061","article-title":"Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B","volume":"123","author":"Di Martino","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eimc.2010.02.001_bib15","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1111\/j.1365-2893.2007.00917.x","article-title":"Treatment of chronic hepatitis D","volume":"14","author":"Farci","year":"2007","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.eimc.2010.02.001_bib16","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1365-2893.2003.00450.x","article-title":"Peginterferon alpha-2a 40kDa: An advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"10","author":"Cooksley","year":"2003","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.eimc.2010.02.001_bib17","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2010.02.001_bib18","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/hep.510260634","article-title":"A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum","volume":"26","author":"Lampertico","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2010.02.001_bib19","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1111\/j.1572-0241.2007.01449.x","article-title":"A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B","volume":"102","author":"Gish","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.eimc.2010.02.001_bib20","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199910213411702","article-title":"Lamivudine as initial treatment for chronic hepatitis B in the United States","volume":"341","author":"Dienstag","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2010.02.001_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM199807093390201","article-title":"A one-year trial of lamivudine for chronic hepatitis B","volume":"339","author":"Lai","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2010.02.001_bib22","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/gut.46.4.562","article-title":"Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial","volume":"46","author":"Schalm","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.eimc.2010.02.001_bib23","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/gast.2000.8559","article-title":"Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B","volume":"119","author":"Liaw","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eimc.2010.02.001_bib24","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1053\/jhep.2001.25084","article-title":"Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy","volume":"33","author":"Leung","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2010.02.001_bib25","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1440-1746.2004.03428.x","article-title":"Four years of lamivudine treatment in Chinese patients with chronic hepatitis B","volume":"19","author":"Chang","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.eimc.2010.02.001_bib26","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1053\/jhep.2003.50117","article-title":"Durability of serologic response after lamivudine treatment of chronic hepatitis B","volume":"37","author":"Dienstag","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2010.02.001_bib27","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1007\/s10620-008-0508-3","article-title":"Durability of antiviral response in HBeAg-positive chronic hepatitis B patients who maintained virologic response for one year after lamivudine discontinuation","volume":"54","author":"Kim","year":"2009","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.eimc.2010.02.001_bib28","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1053\/jhep.2003.50458","article-title":"Determinants for sustained HBeAg response to lamivudine therapy","volume":"38","author":"Chien","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2010.02.001_bib29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/135965350400900208","article-title":"No benefit to continue lamivudine therapy after emergence of YMDD mutations","volume":"9","author":"Liaw","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2010.02.001_bib30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2036.2004.01845.x","article-title":"Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants","volume":"19","author":"Wong","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.eimc.2010.02.001_bib31","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1053\/jhep.2000.17915","article-title":"Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B","volume":"32","author":"Hadziyannis","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2010.02.001_bib32","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0168-8278(00)80076-8","article-title":"Long-term follow-up of patients with anti-HBe\/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine","volume":"32","author":"Santantonio","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.eimc.2010.02.001_bib33","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"348","author":"Marcellin","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2010.02.001_bib34","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B","volume":"348","author":"Hadziyannis","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2010.02.001_bib35","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","article-title":"Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years","volume":"131","author":"Hadziyannis","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eimc.2010.02.001_bib36","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hep.21534","article-title":"Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B","volume":"45","author":"Rapti","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2010.02.001_bib37","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2036.2007.03567.x","article-title":"Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine","volume":"27","author":"Manolakopoulos","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.eimc.2010.02.001_bib38","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jhep.2005.08.020","article-title":"Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1","volume":"44","author":"Benhamou","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.eimc.2010.02.001_bib39","unstructured":"Gesida, Secretar\u00eda del Plan Nacional de Sida SPNS, Asociaci\u00f3n Espa\u00f1ola para el Estudio del H\u00edgado AEEH. Recomendaciones de GESIDA\/PNS\/AEEH sobre tratamiento y manejo del paciente adulto coinfectado por VIH y virus de las hepatitis A, B o C; 2009 [consultado 30\/9\/2009]. Disponible en: http:\/\/www.gesida.seimc.org\/."},{"key":"10.1016\/j.eimc.2010.02.001_bib40","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/hep.22414","article-title":"Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"48","author":"Marcellin","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2010.02.001_bib41","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/lt.20981","article-title":"Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results","volume":"13","author":"Schiff","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.eimc.2010.02.001_bib42","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2010.02.001_bib43","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2010.02.001_bib44","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1053\/j.gastro.2006.04.007","article-title":"Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B","volume":"130","author":"Sherman","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eimc.2010.02.001_bib45","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/hep.21422","article-title":"Entecavir resistance is rare in nucleoside naive patients with hepatitis B","volume":"44","author":"Colonno","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2010.02.001_bib46","doi-asserted-by":"crossref","first-page":"S294","DOI":"10.1016\/S0168-8278(07)62379-4","article-title":"Four year assesment of ETV resistance in nucleoside-naive lamivudine refractory patients","volume":"46","author":"Colonno","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.eimc.2010.02.001_bib47","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1056\/NEJMoa067710","article-title":"The HBV drug entecavir-effects on HIV-1 replication and resistance","volume":"356","author":"McMahon","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2010.02.001_bib48","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.23346","article-title":"Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function","volume":"50","author":"Lange","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2010.02.001_bib49","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","author":"Lai","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2010.02.001_bib50","unstructured":"Telbivudine has activity against HIV [abstract 813a]. 16th Conference on Retroviruses and Opportunistic Infections. 2009 Feb 8-11; Montreal."},{"key":"10.1016\/j.eimc.2010.02.001_bib51","unstructured":"Avila C, Karwowska S, Lai C, Evans T. Telbivudine has no in vitro activity against laboratory and clinical HIV-1, including 5 clades and drug-resistant clinical isolates [abstract 813b]. 2009"},{"key":"10.1016\/j.eimc.2010.02.001_bib52","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"EASL Clinical Practice Guidelines: Management of chronic hepatitis B","volume":"50","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.eimc.2010.02.001_bib53","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archinte.166.1.49","article-title":"A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B","volume":"166","author":"Lim","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.eimc.2010.02.001_bib54","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1053\/jhep.2001.20899","article-title":"Antiviral activity of clevudine [L-FMAU, 1-2-fluoro-5-methyl-beta, L-arabinofuranosyl uracil] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks Marmota monax","volume":"33","author":"Peek","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2010.02.001_bib55","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/hep.22959","article-title":"Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA","volume":"49","author":"Seok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2010.02.001_bib56","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.3748\/wjg.15.1805","article-title":"Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides","volume":"15","author":"Keeffe","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.eimc.2010.02.001_bib57","doi-asserted-by":"crossref","first-page":"930","DOI":"10.2174\/092986708783955383","article-title":"Viral hepatitis B: Established and emerging therapies","volume":"15","author":"Balsano","year":"2008","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.eimc.2010.02.001_bib58","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2010.02.001_bib59","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1038\/ajg.2009.311","article-title":"Peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus","volume":"104","author":"Gluud","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.eimc.2010.02.001_bib60","doi-asserted-by":"crossref","unstructured":"Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009 Sep 17;461:399\u2013401.","DOI":"10.1038\/nature08309"},{"key":"10.1016\/j.eimc.2010.02.001_bib61","unstructured":"Rallon N, Naggie S, Benito J, Medrano J, Restrepo C, Goldstein D, et al. Strong Association of a Single Nucleotide Polymorphism Located Near the Interleukin-28b Gene with Response to Hepatitis C Therapy in HIV\/HCV Co-infected Patients. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA. February 16\u201319, 2009. Abstract 165LB."},{"key":"10.1016\/j.eimc.2010.02.001_bib62","doi-asserted-by":"crossref","unstructured":"Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-wide Association Study. Gastroenterology. 2010 Jan 11. [Epub ahead of print].","DOI":"10.1053\/j.gastro.2009.12.056"},{"key":"10.1016\/j.eimc.2010.02.001_bib63","doi-asserted-by":"crossref","unstructured":"Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009 Oct 8;461:798\u2013801.","DOI":"10.1038\/nature08463"},{"key":"10.1016\/j.eimc.2010.02.001_bib64","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2010.02.001_bib65","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"Hezode","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2010.02.001_bib66","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.bpg.2008.12.002","article-title":"Future treatment options for HCV: Double, triple, what is the optimal combination?","volume":"22","author":"Kronenberger","year":"2008","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.eimc.2010.02.001_bib67","unstructured":"FDA FDA MedWatch-relenza zanamivir inhalation powder must not be reconstituted in liquid formulation or used in any nebulizer or mechanical ventilator [consultado 30\/10\/2009] Disponible en: http:\/\/www.drugs.com\/news\/fda-medwatch-relenza-zanamivir-inhalation-powder-must-not-reconstituted-liquid-formulation-any-20299.html"},{"key":"10.1016\/j.eimc.2010.02.001_bib68","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1001\/archinte.163.14.1667","article-title":"Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations","volume":"163","author":"Kaiser","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.eimc.2010.02.001_bib69","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1093\/ndt\/gfl267","article-title":"The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis","volume":"21","author":"Robson","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.eimc.2010.02.001_bib70","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/591851","article-title":"Developing new antiviral agents for influenza treatment: what does the future hold?","volume":"48","author":"Hayden","year":"2009","journal-title":"Clin Infect Dis"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X10000662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X10000662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T20:32:06Z","timestamp":1685565126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X10000662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0213005X10000662"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2010.02.001","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}